HomeThe Merck Access Program
Prescribing InformationMedication Guide
Additional Products

Select Cancer Type for Billing Codes

NDC and Billing Codes for KEYTRUDA QLEX

Melanoma: Advanced and Adjuvant Settings

NSCLC: Advanced, Adjuvant, and Neoadjuvant Followed by Adjuvant Settings

Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Locally Advanced and Metastatic or Unresectable, Recurrent HNSCC

Advanced Urothelial Cancer

Cisplatin-Ineligible Muscle Invasive Bladder Cancer

High-Risk Non-Muscle Invasive Bladder Cancer

Advanced MSI-H/dMMR Cancers

Advanced MSI-H/dMMR CRC

Advanced Gastric or GEJ Adenocarcinoma

Advanced Esophageal or GEJ Carcinoma

Advanced Cervical Cancer

Hepatocellular Carcinoma

Advanced Biliary Tract Cancer

Advanced Merkel Cell Carcinoma

RCC: Advanced and Adjuvant Settings

Endometrial Carcinoma

Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced cSCC

High-Risk Early-Stage TNBC and Advanced TNBC

Platinum-Resistant Ovarian Cancer

Selected Indications for KEYTRUDA® (pembrolizumab)

Selected Safety Information for KEYTRUDA® (pembrolizumab)

This site is intended for health care professionals in the United States, its territories, and Puerto Rico.

Merck LogoTerms of UsePrivacy PolicyCookie PreferencesAccessibilityYour Privacy ChoicesConsumer Health Data Privacy Policy

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-KEY-XXXXXX XX/XX